Database : HANSEN Search on : SARCOMA DE KAPOSI/QUIMIOTER [Subject descriptor] References found : 2 [refine] Displaying: 1 .. 2   in format [Detailed]

page 1 de 1

1 / 2

HANSEN

select to print

Id: 13963 Author: Okafor, Mark C Title: Thalidomide for erythema nodosum leprosum and other applications ..- Source: s.l; s.n; 2003. 13 p. tab. Abstract: Thalidomide, administered as a sedative and antiemetic decades ago, was considered responsible for numerous devastating cases of birth defects and consequently was banned from markets worldwide. However, the drug remarkably has resurfaced with promise of immunomodulatory benefit in a wide array of immunologic disorders for which available treatments were limited. It is approved by the Food and Drug Administration for erythema nodosum leprosum (ENL). Although the relative paucity of leprosy and ENL worldwide may perceivably limit interest in and knowledge about thalidomide, increasing numbers of new and potential uses expand its applicability widely beyond ENL. Thalidomide, an inhibitor of tumor necrosis factor a, is the best known agent for short-term treatment of ENL skin manifestations, as well as postremission maintenance therapy to prevent recurrence. For this indication, it is effective as monotherapy and as part of combination therapy with corticosteroids. Studies of thalidomide in chronic graft-versus-host disease showed benefit in children and adults as treatment, but not as prophylaxis. The agent has been administered successfully for treatment of cachexia related to cancer, tuberculosis, and human immunodeficiency virus infection, although evidence of efficacy is inconclusive. Thalidomide monotherapy effectively induced objective response in trials in patients with both newly diagnosed and advanced or refractory multiple myeloma. Combination therapy with thalidomide and corticosteroids was also effective in these patients, as well as in treatment of aphthous and genital ulcers. Limited evidence supports the drug's benefit in treatment of Kaposi's sarcoma. Other thalidomide applications include Crohn's disease, rheumatoid arthritis, and multiple sclerosis. Somnolence, constipation, and rash were the most frequently cited adverse effects in studies, but thalidomide-induced neuropathy and idiopathic thromboembolism were critical causes for drug discontinuation. Thalidomide is still contraindicated in pregnant women, women of childbearing age, and sexually active men not using contraception. Clinicians should be conversant with thalidomide in ENL (its primary application) in the natural course of leprosy, as well as in the agent's other applications. (AU). Descriptors: CAQUEXIA/quimioter ERITEMA NODOSO/quimioter DOENCA ENXERTO-HOSPEDEIRO/quimioter HANSENIASE VIRCHOWIANA/quimioter MIELOMA MULTIPLO/quimioter EDUCACAO DO PACIENTE/métodos SARCOMA DE KAPOSI/quimioter TALIDOMIDA/ef adv TALIDOMIDA/uso terap Limits: HUMANO ANIMAL Electronic Medium: http://www.ilsl.br Location: BR191.1; 09149/s

2 / 2

HANSEN

select to print

Id: 12316 Author: Geraminejad, Pedram; Memar, Omeed; Aronson, Iris; Rady, Peter L; Hengge, Ulrich; Tyring, Stephen K Title: Kaposi's sarcoma and other manifestations of human herpesvirus 8 ..- Source: s.l; s.n; Nov. 2002. 15 p. ilus, tab. Abstract: Kaposi's sarcoma (KS) was described by Moritz Kaposi in 1872 and was known for an entire century as a rare disorder of older men usually of Eastern European, Mediterranean, and/or Jewish origin. In the early 1980s, the prevalence of KS began to increase dramatically and soon became the most common malignancy in patients with AIDS, especially those who were male homosexuals. In 1994, a new human herpesvirus (HHV) was found to be present in almost 100% of KS lesions. This virus was found to be a gammaherpesvirus, closely related to Epstein-Barr virus, and was designated HHV-8. Subsequently, HHV-8 DNA was found in almost all specimens of classic KS, endemic KS, and iatrogenic KS, as well as epidemic KS (ie, AIDS KS). It is now believed that HHV-8 is necessary, but not sufficient, to cause KS and that other factors such as immunosuppression play a major role. The use of highly active antiretroviral therapy (HAART) since 1996 has markedly reduced the prevalence of AIDS KS in western countries, but because 99% of the 40 million patients with AIDS in the world cannot afford HAART, KS is still a very common problem. Primary effusion lymphoma and multicentric Castleman's disease are also thought to be due to HHV-8. Although HHV-8 DNA has been described in a number of other cutaneous disorders, there is little evidence that HHV-8 is of etiologic significance in these diseases. The mechanism by which HHV-8 causes KS, primary effusion lymphoma, and multicentric Castleman's disease is not well understood but is thought to involve a number of molecular events, the study of which should further our understanding of viral oncology. (J Am Acad Dermatol 2002;47:641-55.) Learning objective: At the completion of this learning activity, participants should be familiar with Kaposi's sarcoma and other manifestations of human herpesvirus 8.. Descriptors: PRODUTOS DO GENE TAT INFECÇOES POR HERPESVIRIDAE HIPERPLASIA DO LINFONODO GIGANTE INTERLEUCINA-6 LINFOMA DE CÉLULA-B LINFOMA DE CÉLULA-B SARCOMA DE KAPOSI SARCOMA DE KAPOSI SARCOMA DE KAPOSI SARCOMA DE KAPOSI TERAPIA ANTI-RETROVIRAL DE ALTA ATIVIDADE FASES DE LEITURA ABERTA/fisiologia HERPESVIRUS 8 HUMANO/fisiologia ESTUDOS SOROEPIDEMIOLOGICOS Limits: HUMANO Location: BR191.1; 0274/cme

---

page 1 de 1

Refine the search

Database : HANSEN

Advanced form

Search for : Free form

		Search	in field
1			WordsTitle wordsAbstract wordsAuthorInstitutional authorSubject descriptorLimitsLanguageCountry, year publicationJournalType of literatureBibliographic levelMonography in seriesPublication typeConferenceUnique identifierLocationElectronic supportEntry dateRecord type
2	and or and not		WordsTitle wordsAbstract wordsAuthorInstitutional authorSubject descriptorLimitsLanguageCountry, year publicationJournalType of literatureBibliographic levelMonography in seriesPublication typeConferenceUnique identifierLocationElectronic supportEntry dateRecord type
3	and or and not		WordsTitle wordsAbstract wordsAuthorInstitutional authorSubject descriptorLimitsLanguageCountry, year publicationJournalType of literatureBibliographic levelMonography in seriesPublication typeConferenceUnique identifierLocationElectronic supportEntry dateRecord type

Search engine: iAH powered by WWWISIS

IAH - © BIREME/PAHO/WHO Latin American and Caribbean Center on Health Sciences Information